Impact ledger
Galectin Therapeutics Inc. (GALT)
2 events mapped to this ticker since 2026-06-23.
Assumption changes
| Date | Assumption | Direction | Magnitude | Conf. |
|---|---|---|---|---|
| 2026-06-23 | share_count | Bullish | — | 0.70 |
| 2026-06-23 | net_debt | Bullish | — | 0.70 |
| 2026-06-23 | revenue | Bullish | — | 0.70 |
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-06-23 | Event | Strategic partnerships can provide non-dilutive funding, share development costs, and leverage larger pharmaceutical companies' commercialization infrastructure, significantly de-risking the asset and potentially accelerating market entry. | Bullish | 3-12m | 0.80 |
| 2026-06-23 | Event | Regulatory clarity significantly de-risks the development of belapectin, increasing the probability of successful Phase 3 trials and eventual market approval. This positive FDA interaction validates the drug's potential and the company's development strategy. | Bullish | 1-3m | 0.90 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for GALT, start a trial or view the GALT entity page.